CORT — Corcept Therapeutics Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousLarge CapHigh Flyer

Annual income statement for Corcept Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	354	366	402	482	675
Cost of Revenue
Gross Profit	348	361	396	476	664
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses	226	242	289	375	538
Operating Profit	128	124	113	107	137
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	132	125	116	125	161
Provision for Income Taxes
Net Income After Taxes	106	113	101	106	141
Net Income Before Extraordinary Items
Net Income	106	113	101	106	141
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	106	113	101	106	141
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.854	0.893	0.875	0.95	1.24